Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F17%3A43913023" target="_blank" >RIV/00216208:11120/17:43913023 - isvavai.cz</a>

Alternative codes found

RIV/00064173:_____/17:N0000027

Result on the web

<a href="http://dx.doi.org/10.1200/JCO.2016.71.3289" target="_blank" >http://dx.doi.org/10.1200/JCO.2016.71.3289</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1200/JCO.2016.71.3289" target="_blank" >10.1200/JCO.2016.71.3289</a>

Result language

angličtina

Original language name

Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials

Original language description

Purpose: Clinical characteristics, therapeutic approaches, and prognosis of late relapse (LR) in patients with classic Hodgkin lymphoma (cHL) are poorly understood. We performed a comprehensive analysis of LR of Hodgkin lymphoma (LR-HL). Methods. To estimate the incidence of LR-HL, we retrospectively analyzed 6,840 patients with cHL included in the German Hodgkin Study Group trials HD7 to HD12. Patients who experienced a relapse &gt;5 years into remission were compared with patients in continued remission for &gt;5 years and with those who experienced a relapse &lt;= 5 years after first diagnosis. Conclusion. Apart from treatment-associated adverse effects, survivors after initially successful therapy for cHL are at an 85-fold risk for recurrence of disease compared with the general German population. After risk-adapted treatment strategies, especially in early-stage favorable HL, regular clinical follow-up is recommended for timely detection of LR-HL. With adequate treatment, prognosis of LR-HL is better compared with early relapses. (C) 2017 by American Society of Clinical Oncology

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of Clinical Oncology

ISSN

0732-183X

e-ISSN

—

Volume of the periodical

35

Issue of the periodical within the volume

13

Country of publishing house

US - UNITED STATES

Number of pages

7

Pages from-to

1444-1450

UT code for WoS article

000400335500010

EID of the result in the Scopus database

2-s2.0-85018347722